A Phase I, Single-centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics After Oral Single Ascending Doses of AZD2516 in Young and Elderly Japanese Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2010
At a glance
- Drugs AZD 2516 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- 05 Mar 2010 Actual patient number (40) added as reported by ClinicalTrials.gov.
- 05 Mar 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 05 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.